Journal of Nanomedicine & Nanotechnology

Dendrimer delivery of phenolic compounds to tumour-associated macrophages to improve anti-metastatic efficacy and reduce toxicity in metastatic cancer

26^th International Conference on ADVANCED NANOSCIENCE AND NANOTECHNOLOGY

December 05-06, 2022 | Dubai, UAE

Rikesh Shah

Rikeshâ??s Remedies Corporation, United Kingdom

Keynote: J Nanomed Nanotechnol

Abstract:

Metastasis is a major concern regarding cancer because 90% of cancer deaths are caused by metastasis. Nuclear Factor-κB (NF-κB) has been shown to be an essential modulator of metastasis. Tumour-associated macrophages (TAMs) have been the main target for metastatic cancer. TAMs promote metastasis via NF-κB signalling by expressing an M2 phenotype with the potential of reducing metastasis. A series of phenolic compounds have been shown to prevent TAMs from acquiring an M2 phenotype. The use of nanobiotechnology is rapidly emerging because of its ability to target specific cells in the organism, and controlled drug release at these cells. PAMAM dendrimers are the most suitable drug delivery systems to target TAMs because they allow the targeting of various cells by attaching ligands to their surface and allow controlled drug release via pH linkers. I have designed a product that uses nanobiotechnology in the form of PAMAM dendrimers which target TAMs using a peptide ligand followed by the conjugation of the phenolic compound via a pH linker. This will drop the phenolic compound at the TAM, which will reduce NF-κB expression, prevent TAMs from acquiring an M2 phenotype, and therefore reduce metastasis. Recent publications 1. Rikesh Shah (2022). NF-κB the key “factor” in breast cancer metastasis (under review)

Biography :

Rikesh Shah is cancer and medical researcher who has 8 years’ experience in cancer, immunology, and business since starting university. Since then, Rikesh has been conducting cancer research during the COVID-19 pandemic. This research has led to the design of his own product using nanobiotechnology in the form of PAMAM dendrimers to create an original anti-cancer medicine that also reduces the prognosis of patients with RA. Rikesh then created his own pharmaceutical company based on this combining the effectiveness of the product and his business skills.